The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLLl, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLLl, MLL2, MLL fusion proteins, and/or menin.